26.03.2020 • NewsDede WillamsEPAglyphosate

NRDC Sues EPA Over Glyphosate Reapproval

NRDC Sues EPA Over Glyphosate Reapproval (c) Huntstock/Getty Images
NRDC Sues EPA Over Glyphosate Reapproval (c) Huntstock/Getty Images

US-based international environmental advocacy groups Natural Resources Defense Council  (NRDC) and the Pesticide Action Network pressure group (PAN) are suing the US Environmental Protection Agency (EPA)  over its reapproval of the widely used pesticide glyphosate.

By reapproving the use of the pesticide, the administration of US president Donald Trump is putting both public health and the environment – in particular pollinators – at risk and is once again ignoring science, the NGOs said.

 “By rubber-stamping the reapproval of glyphosate, the EPA ignored warnings from the scientific and environmental community,” Sylvia Fallon, senior director of NRDC’s wildlife division, commented.

The advocacy group has fought for nearly a decade to restrict the use of glyphosate, the active ingredient in the weed-killing product Roundup, for which it blames birth defects and non-Hodgkin’s lymphoma.

The latter disease also is at the center of the US lawsuits against Bayer, of which 43,000 are currently pending.

To address the looming biodiversity crisis faced by pollinators and thousands of other high-risk species, NRDC said it continues to advocate for effective, affordable, and non-chemical alternatives for controlling weeds.

 

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.